Zanubrutinib Plus Rituximab As Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Status:
RECRUITING
Trial end date:
2028-09-30
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Zanubrutinib in combination with Rituximab as a first-line treatment for patients with mucosa-associated lymphoid tissue (MALT) extranodal marginal zone lymphoma.
Phase:
PHASE2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Beijing Tongren Hospital Fifth Affiliated Hospital of Guangzhou Medical University Fifth Affiliated Hospital, Sun Yat-Sen University Gansu Cancer Hospital Shenzhen People's Hospital Tongji Medical College of Huazhong University of Science & Technology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology